I would posit that leronlimab has at least some efficacy as shown by anecdotal evidence. The problem has been poor trial design resulting from expert a lack of expertise in designing the trials in the first place.
Letting Bruce Patterson slip away was like letting some superstar athlete become a free agent.
Market Data 
Markets 
AI
